A phase 3, randomized, double blind, multinational trial of intravenous telavancin versus vancomycin for treatment of complicated Gram positive skin and skin structure infections with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

Trial Profile

A phase 3, randomized, double blind, multinational trial of intravenous telavancin versus vancomycin for treatment of complicated Gram positive skin and skin structure infections with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2016

At a glance

  • Drugs Telavancin (Primary) ; Vancomycin
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Skin infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-II
  • Sponsors Theravance
  • Most Recent Events

    • 09 May 2016 According to a Theravance Biopharma media release, the US FDA has approved the company's sNDA for VIBATIV (telavancin) to expand the product's label to include data describing the treatment of patients with concurrent Staphylococcus aureus bacteremia in both of the antibiotic's currently approved indications in the United States (HABP/VABP). The sNDA was approved based on combined data from the ATLAS I and II and ATTAIN I and II trials.
    • 10 Sep 2015 According to Theravance Biopharma media release, the US FDA has accepted for filing the company's supplemental NDA.
    • 30 Jun 2015 According to Theravance Biopharma media release, telavancin (VIBATIV) has receieved marketing authorization in Russia for the treatment of multiple infections caused by gram positive bacteria including MRSA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top